Q-omics provides the consensus-scored MYO5C profile across patient tissues and cancer cell-line models. MYO5C expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MYO5C is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MYO5C RNA expression shows 20,498 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, and KIRP as cancer lineages where MYO5C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYO5C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYO5C survival associations across molecular data types. MYO5C RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYO5C RNA expression–survival associations across cancer types. High MYO5C expression shows unfavorable associations in UVM, LGG and PAAD, but favorable associations in KIRC, UCEC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MYO5C RNA expression.
This table summarizes MYO5C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MYO5C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYO5C shows lower tumor expression in KIRC, LUSC, HNSC and THCA and higher tumor expression in LIHC and STAD. The KIRC box plot shows higher MYO5C RNA expression in normal versus tumor tissue (log2 FC = −1.303, t-test p < 0.001).
This table shows molecular features associated with MYO5C in patient tissues and cancer cell lines. In patient samples, MYO5C shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, MYO5C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
